Compare Gilead Sciences, Inc. (GILD) vs Seagate Technology Holdings PLC (STX) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

STX trades at $753.18, down 14.25% in the past 24 hours amid broader market volatility. The stock exhibits strong fundamentals with a 21.6% net income margin and consistent earnings beats, but valuation ratios like a P/E of 78.59 and P/B of 171.15 suggest premium pricing. Technical indicators are bearish, with support near $743, while analyst sentiment remains positive with a $987.86 consensus price target. Recent news highlights AI-driven storage demand and a Wells Fargo upgrade on July 10, 2026.

Outlook: STX benefits from robust AI infrastructure demand and margin expansion, but high debt levels and intense competition pose risks. The stock offers upside if earnings growth persists, yet investors should monitor debt sustainability and competitive pressures. Near-term volatility is likely around the Q2 2026 earnings report on July 28, 2026.